122 related articles for article (PubMed ID: 6292647)
1. CCK receptors and human neurological disease.
Hays SE; Paul SM
Life Sci; 1982 Jul; 31(4):319-22. PubMed ID: 6292647
[TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin receptors are decreased in basal ganglia and cerebral cortex of Huntington's disease.
Hays SE; Goodwin FK; Paul SM
Brain Res; 1981 Nov; 225(2):452-6. PubMed ID: 6272931
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin peptides and receptor binding in Alzheimer's disease.
Löfberg C; Harro J; Gottfries CG; Oreland L
J Neural Transm (Vienna); 1996; 103(7):851-60. PubMed ID: 8872869
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptides in Alzheimer's disease, depression and schizophrenia. A post mortem analysis of vasoactive intestinal peptide and cholecystokinin in cerebral cortex.
Perry RH; Dockray GJ; Dimaline R; Perry EK; Blessed G; Tomlinson BE
J Neurol Sci; 1981 Sep; 51(3):465-72. PubMed ID: 6268760
[TBL] [Abstract][Full Text] [Related]
5. The nucleus basalis in Huntington's disease.
Clark AW; Parhad IM; Folstein SE; Whitehouse PJ; Hedreen JC; Price DL; Chase GA
Neurology; 1983 Oct; 33(10):1262-7. PubMed ID: 6225032
[TBL] [Abstract][Full Text] [Related]
6. Alterations of brain cerebral cortex CCK receptors in the ob/ob mouse.
Saito A; Williams JA; Goldfine ID
Endocrinology; 1981 Sep; 109(3):984-6. PubMed ID: 6266818
[TBL] [Abstract][Full Text] [Related]
7. Cholinergic receptor binding and autoradiography in brains of non-neurological and senile dementia of Alzheimer-type patients.
Lang W; Henke H
Brain Res; 1983 May; 267(2):271-80. PubMed ID: 6871676
[TBL] [Abstract][Full Text] [Related]
8. Alterations in 3H-GABA binding in Huntington's chorea.
Lloyd KG; Dreksler S; Bird ED
Life Sci; 1977 Sep; 21(5):747-53. PubMed ID: 198624
[No Abstract] [Full Text] [Related]
9. Neuropeptides in neurological disease.
Beal MF; Martin JB
Ann Neurol; 1986 Nov; 20(5):547-65. PubMed ID: 2947536
[TBL] [Abstract][Full Text] [Related]
10. Postmortem studies of peptides in Alzheimer's disease and Huntington's disease.
Rossor M; Emson P; Dawbarn D; Dockray G; Mountjoy C; Roth M
Res Publ Assoc Res Nerv Ment Dis; 1986; 64():259-77. PubMed ID: 2425405
[No Abstract] [Full Text] [Related]
11. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease.
Bowen DM; Allen SJ; Benton JS; Goodhardt MJ; Haan EA; Palmer AM; Sims NR; Smith CC; Spillane JA; Esiri MM; Neary D; Snowdon JS; Wilcock GK; Davison AN
J Neurochem; 1983 Jul; 41(1):266-72. PubMed ID: 6306169
[TBL] [Abstract][Full Text] [Related]
12. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes.
Dragunow M; Faull RL; Lawlor P; Beilharz EJ; Singleton K; Walker EB; Mee E
Neuroreport; 1995 May; 6(7):1053-7. PubMed ID: 7632894
[TBL] [Abstract][Full Text] [Related]
13. Reduction in cholecystokinin-like immunoreactivity in the basal ganglia in Huntington's disease.
Emson PC; Rehfeld JF; Langevin H; Rossor M
Brain Res; 1980 Oct; 198(2):497-500. PubMed ID: 6447532
[No Abstract] [Full Text] [Related]
14. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease.
De Souza EB; Whitehouse PJ; Folstein SE; Price DL; Vale WW
Brain Res; 1987 Dec; 437(2):355-9. PubMed ID: 2893655
[TBL] [Abstract][Full Text] [Related]
15. [3H]nitrendipine binding in temporal cortex in Alzheimer's and Huntington's diseases.
Piggott MA; Candy JM; Perry RH
Brain Res; 1991 Nov; 565(1):42-7. PubMed ID: 1663418
[TBL] [Abstract][Full Text] [Related]
16. Cerebral metabolic relationships for selected brain regions in Alzheimer's, Huntington's, and Parkinson's diseases.
Metter EJ; Riege WH; Kameyama M; Kuhl DE; Phelps ME
J Cereb Blood Flow Metab; 1984 Dec; 4(4):500-6. PubMed ID: 6238975
[TBL] [Abstract][Full Text] [Related]
17. Disease-related protein changes in purified neurons from Alzheimer's and Huntington's diseases.
Selkoe DJ
Trans Am Neurol Assoc; 1979; 104():70-4. PubMed ID: 162259
[No Abstract] [Full Text] [Related]
18. Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease.
Ellison DW; Beal MF; Martin JB
Brain Res; 1987 Aug; 417(2):389-92. PubMed ID: 2958109
[TBL] [Abstract][Full Text] [Related]
19. Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders.
Ge J; Barnes NM
Eur J Pharmacol; 1996 Feb; 297(3):299-306. PubMed ID: 8666063
[TBL] [Abstract][Full Text] [Related]
20. Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases.
Greenamyre JT; Penney JB; Young AB; D'Amato CJ; Hicks SP; Shoulson I
Science; 1985 Mar; 227(4693):1496-9. PubMed ID: 2858129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
